Rikke

About PlusR

This author has not yet filled in any details.
So far PlusR has created 891 blog entries.

KalVista to present HAE attack journey data at 2024 HAEi Regional Conference Americas

2024-03-09T11:34:54+01:00March 8, 2024|HAEi News|

KalVista Pharmaceuticals to present HAE attack journey data at 2024 HAEi Regional Conference Americas KalVista Pharmaceuticals today announced the acceptance of multiple abstracts at the 2024 HAEi Regional Conference meeting taking place in Panama City, Panama from 15-17 March 2024. KalVista is a Silver-level sponsor of the meeting. The presentations are: Relationship Between Time [...]

Astria reports Q4 and full year 2023 financial results and provides a corporate update

2024-03-07T21:24:09+01:00March 4, 2024|HAEi News|

Astria Therapeutics reports fourth quarter and full year 2023 financial results and provides a corporate update Astra Therapeutics today announced today reported financial results for the fourth quarter and full year ended 31 December 2023, and provided a corporate update. Jill C Milne, Chief Executive Officer at Astria Therapeutics, said: “We have strong conviction [...]

BioCryst reports Q4 and full year 2023 financial results and upcoming key milestones

2024-02-28T11:58:05+01:00February 26, 2024|HAEi News|

BioCryst reports fourth quarter and full year 2023 financial results and upcoming key milestones Biocryst Pharmaceuticals Inc today reported financial results for the fourth quarter and full year ended 31 December 2023, and provided a corporate update. Jon Stonehouse, President and Chief Executive Officer of BioCryst. “The impressive growth we are seeing with Orladeyo [...]

KalVista presents additional phase-3 KONFIDENT data at the 2024 AAAAI Annual Meeting

2024-02-28T11:51:54+01:00February 26, 2024|HAEi News|

KalVista Pharmaceuticals presents additional phase-3 KONFIDENT data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting KalVista Pharmaceuticals today announced that it presented additional data on its phase 3 KONFIDENT trial for sebetralstat, including a more in-depth analysis of sebetralstat efficacy and safety at the 2024 American Academy of Allergy, Asthma [...]

KalVista presents data on unmet needs in HAE from a Patient Perspective at the 2024 AAAAI Annual Meeting

2024-02-28T11:49:37+01:00February 26, 2024|HAEi News|

KalVista Pharmaceuticals presents data on unmet needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting KalVista Pharmaceuticals today announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the 2024 American Academy [...]

BioCryst presents new real-world data showing rapid, substantial and sustained HAE attack rate reductions after beginning Orladeyo (berotralstat) treatment

2024-02-25T10:09:34+01:00February 23, 2024|HAEi News|

BioCryst presents new real-world data showing rapid, substantial and sustained HAE attack rate reductions after beginning Orladeyo (berotralstat) treatment Biocryst Pharmaceuticals Inc today announced new analyses of real-world use of oral, once-daily Orladeyo (berotralstat) that showed patients who initiated Orladeyo experienced rapid, substantial and sustained reductions in attack rates through 18 months of treatment [...]

Intellia announces Q4 and full-year 2023 financial results and highlights company progress

2024-02-25T10:04:09+01:00February 22, 2024|HAEi News|

Intellia Therapeutics announces fourth quarter and full-year 2023 financial results and highlights recent company progress Intellia Therapeutics today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2023. Intellia President and Chief Executive Officer, John Leonard MD, said: “We’re off to a very strong start in 2024 as [...]

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

2024-02-28T12:00:48+01:00February 22, 2024|HAEi News|

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting Pharvaris today announced the upcoming presentation of two posters at the American Academy of Allergy, Asthma, & Immunology (AAAAI) 2024 Annual Scientific Meeting, to be held in Washington DC from [...]

Astria to present at upcoming AAAAI Annual Meeting

2024-02-22T21:41:14+01:00February 20, 2024|HAEi News|

Astria Therapeutics to present at upcoming American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Astra Therapeutics today announced that it will present final STAR-0215 Phase 1a healthy subject data at the upcoming American Academy of Allergy, Asthma, & Immunology (AAAAI) Annual Meeting in Washington, D.C. on February 23, 2024 at 3:15pm Eastern [...]

BioCryst launches Orladeyo (berotralstat) in Italy

2024-02-26T15:32:37+01:00February 19, 2024|HAEi News|

BioCryst launches Orladeyo (berotralstat) in Italy BioCryst Pharmaceuticals Inc today announced that the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA), has finalized reimbursement and recommended Orladeyo (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Italy now [...]

Go to Top